Navigation Links
Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Date:9/14/2007

r does matter -- especially when it comes to lung cancer," said James A. Bianco, M.D., president and CEO of CTI. "This should be a national wake up call for increased awareness and research into lung cancer and gender-based medicine. Women are affected by lung cancer differently than men, and they respond differently to treatment. Through our XYOTAX studies, we continue to explore ways to turn a negative -- high levels of estrogen -- into a positive in our continuing efforts to make cancer more treatable."

About XYOTAX(TM)

XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies. XYOTAX is being studied in non-small cell lung and ovarian cancers as well as in several investigator-sponsored trials for prostate and breast cancers.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products a
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
6. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
7. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
8. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
9. Analyzers Offer Point-of-Care Lipid Panels
10. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
11. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Cataracts are the leading cause of ... of Ophthalmology, aging is the leading cause of eye ... natural lens. 22 million Americans age 40 and older ... to age, that number will increase over 30 million. ... iPads, smart-phones and computers, the demographic of ages 40 ...
(Date:6/18/2013)... , June 18, 2013  Decision Resources, ... firms for pharmaceutical and healthcare issues, announces that ... of the Middle East ... Tracker analyzes the challenges and opportunities to gaining ... international regions comprising 24 countries. The countries covered ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 ... Gilead Sciences, Inc. (NASDAQ: GILD ), Health Management ... (NASDAQ: IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ... readers may access these reports free of charge - including ... the links below. Gilead Sciences, Inc. Research Report ...
Breaking Medicine Technology:New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
... a compression garment distributor, has announced that the redesigned ... An alternative to compression stockings , the garments ... knee and thigh, and resemble an athletic brace. ... been out for several years, but they recently made ...
... Calif., Dec. 14, 2011  Amgen (NASDAQ: AMGN ) ... tender offer, which expired at 12:00 midnight, New York City ... has accepted for purchase 83,333,333 shares of its common stock ... cost of approximately $5 billion, excluding fees and expenses relating ...
Cached Medicine Technology:BrightLife Direct Introduces Redesigned Solaris ReadyWrap Quick-Fit 2Amgen Announces Final Results of Its Tender Offer 2Amgen Announces Final Results of Its Tender Offer 3
(Date:6/18/2013)... June 18, 2013 David Connett, DO, ... Family Medicine for the College of Osteopathic Medicine of ... has been elected president of the Osteopathic Medical ... Brown Jr. appointed Connett, a 1984 alumnus of COMP, ... recently elected Connett to the position during a conference ...
(Date:6/18/2013)... N.Y., June 18, 2013 -- Lauren Sciences, a ... V-Smart nanovesicle platform technology, announced today that it ... Drug Delivery with its V-Smart Platform, and selected ... by MCD Group. , The report, ... Start-ups and Emerging Companies ," features companies MCD ...
(Date:6/18/2013)... enrolled their first patients in the ROADSTER Study, a ... to help clear blockages in carotid arteries and prevent ... in the United States are diagnosed with blockages, or ... blockages can slow or even stop blood flow to ... as a "brain attack." , Current treatment options ...
(Date:6/18/2013)... scrambling to gather data for the FDA to support ... injury in the United States. The University of Rochester ... the Journal of Neurotrauma that it might ... of one., Jeffrey J. Bazarian, M.D., M.P.H., an associate ... first to show that measuring a combination of two ...
(Date:6/18/2013)... system using a person,s DNA was announced as ... London Startup Competition, Europe,s largest technology conference. ... on University of Bristol research by its founders, ... Professor of Bioinformatics in the University,s Department of ... to be one of 16 finalists in the ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center among first to enroll patients for global carotid artery trial 2
... and research on guayule and lesquerella, two native Big Bend ... a Texas AgriLife Research scientist said. , Dr. Mike Foster, ... Center at Lubbock, said he is looking at the possibility ... Trans-Pecos and High Plains. Foster, who is located at the ...
... coverage isn,t reinstated, NEW YORK, Feb. 1 ... to cover Propofol under all circumstances,is getting louder. And ... call to file a consumer fraud lawsuit,against Aetna is ... York State issue has now become a national,campaign., ...
... on MySpace and Facebook, study finds , , FRIDAY, Feb. ... such as MySpace and Facebook have been singled out ... of the unwanted solicitation actually happens in chat rooms ... Even there, only 15 percent of children experience unwanted ...
... Patients with rheumatoid arthritis (RA), the most common ... other individuals to experience depression. Although depression in ... have examined whether rheumatologists and RA patients discuss ... in the February issue of Arthritis Care & ...
... American Heart Association,s ,Go Red for Women, Movement in ... ... As a leader in,cardiovascular treatment and the exclusive Bay Area "hometown" partner ... with the American Heart Association (AHA) to raise awareness,about heart disease, the ...
... (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth ... which demonstrated that ENBREL reduced C-reactive protein (CRP), a ... plaque psoriasis following 12 weeks of treatment. Median ... the ENBREL treated group compared to the placebo treated ...
Cached Medicine News:Health News:Growing markets bring potential for rubber and oilseed crops 2Health News:Growing markets bring potential for rubber and oilseed crops 3Health News:National Health Care Alliance Gains New Members Against Aetna's New Anesthesia Policy 2Health News:National Health Care Alliance Gains New Members Against Aetna's New Anesthesia Policy 3Health News:Social Networking Sites Safer Than IM or Chat Rooms 2Health News:Social Networking Sites Safer Than IM or Chat Rooms 3Health News:Depression not discussed during rheumatoid arthritis doctor visits 2Health News:Abbott 'Goes Red' to Educate Bay Area Women About Heart Disease 2Health News:Abbott 'Goes Red' to Educate Bay Area Women About Heart Disease 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 4Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 5
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... Durable ergonomic chairs with concave seats ... Select options like seats, backrests, armrests, and ... Series for top performance in a variety ... room, static control, health care and office. ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
Medicine Products: